APA 2019: Innovation Lab Grand Prize Winners
On Monday, May 20, a group from the Icahn School of Medicine at Mount Sinai won the $10,000 grand prize at the Psychiatry Innovation Lab at the American Psychiatric Association’s (APA) 2019 Annual Meeting in San Francisco. The APA’s annual “Shark Tank style”...
Hot on the Trail: Schizophrenia
On April 23, Dolores Malaspina, MD, MS, MSPH, published results of a study on marriage duration and how it affects schizophrenia risk in offspring. She found that if a specific man and a woman had a shorter duration of sexual contact before conception, their child...
30 Years on the Forefront of Trauma Research
Dr. Yehuda in Burlington, Vermont, where she was giving a talk about molecular markers of suicide risk in returning veterans. In January, Rachel Yehuda, MS, PhD, was in Israel learning how to use MDMA-assisted psychotherapy to treat PTSD. MDMA, sometimes known as...
Changing the Paradigm for Patients With Treatment-Resistant Depression
The U.S. Food and Drug Administration on March 5 approved SPRAVATO™ (esketamine) CIII nasal spray for the treatment of treatment-resistant depression. Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, is a...
Consortium Sheds New Light on Brain Disorders
More than two dozen researchers at the Icahn School of Medicine at Mount Sinai are advancing brain science by mapping the complex molecular underpinnings of autism spectrum disorder, schizophrenia, and bipolar disorder through their work in the National...
Innovations in Psychiatry: New Treatments for Depression
The Department of Psychiatry’s seventh annual symposium took place on Friday, February 8. The speakers covered emerging treatments for depression including ketamine, deep brain stimulation, and personalized treatment. “This symposium was an...